Novartis Ag

Gregory Hoffman

Frank Peter Stegmeier

Eric Billy

Francesco Hofmann

William Raj Sellers

Craig Stephen Mickanin

Tobias Schmelzle

Michael Ray Schlabach, Jr

Javad Golji

Audrey Kauffmann

Zainab Jagani

Konstantinos John Mavrakis

Earl Robert McDonald, Iii

Antoine De Weck

The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.

Compositions and methods to treat cancer

The invention provides methods of detecting cancer biomarkers, such as one or more SWI/SNF complex mutations, in order to determine a cancer subject's amenability to therapeutic treatment with a BRM inhibitor. Kits, methods of screening for candidate BRM inhibitors, and associated methods of treatment are also provided.

Biomarkers associated with BRM inhibition

Growing community of inventors

Cambridge, MA, United States of America

Gregory Hoffman